Vyant Bio, Inc. Common Stock
VYNT
VYNT已於2023年5月12日下市。
關於： Vyant Bio Inc incorporates biology and data science to improve drug discovery for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. The company's platform is designed to: 1) elucidate disease pathophysiology; 2) formulate key therapeutic hypotheses; 3) identify and validate drug targets, cellular assays, and biomarkers to guide candidate molecule selection; and 4) guide clinical trial patient selection and trial design. The majority of revenue is earned in the United States.
員工： 8
新聞
我們尚未收到任何關於VYNT的最新新聞文章。